Breaking AI & Tech News Analyzed

The LeadMost men in the UK will not be offered prostate cancer screening if the government accepts the final recommendation of an expert committee. The UK National Screening Committee (UKNSC) has concluded that widespread screening using the prostate-specific antigen (PSA) test was "likely to cause more harm than good" despite prostate cancer being the most common cancer in the UK.The Recommendation DetailsThe committee recommended screening only for men with the BRCA2 gene variant who have a family history of certain cancers, suggesting they be screened every two years between the ages of 45 and 61. For this specific group, prostate cancer is more common, develops earlier, and can be more aggressive. Of 100 men with a BRCA2 variant, between 21 and 35 will develop prostate cancer before the age of 80.The committee recommended against screening for other at-risk groups, including black men, citing "ongoing uncertainty on whether screening would cause more good than harm." The main harms of population screening include incontinence and erectile dysfunction in men who do not need treatment for the disease.The Prevalence DataProstate cancer is the most common cancer in the UK, with more than 64,000 men diagnosed every year. However, there is currently no national screening programme for the disease. The UKNSC estimates that its final recommendation would lead to "a few thousand" men being screened for prostate cancer each year.Only around one in every 300 to 400 people will have BRCA gene variations, though as many as one in every 40 Ashkenazi Jewish people carry these variations. In England, the NHS offers free BRCA gene testing for anyone aged 18 or over who has at least one Jewish grandparent.The Impact AnalysisThe decision will come as a blow to campaigners who have voiced support for more widespread screening, including high-profile figures like Sir Chris Hoy, David Cameron, and Sir Stephen Fry. Prostate Cancer UK expressed being "deeply disappointed" with the recommendation, stating that without a screening programme for the UK's most common cancer, "we lose more than 12,000 dads, brothers and partners every single year."However, medical experts argue that screening can reduce deaths from prostate cancer only to a small extent and does not improve overall survival. The challenge remains that once a prostate cancer is found, doctors still can't reliably tell which cancers need treatment and which do not, and treatments can cause long-lasting harm.The Future OutlookThe government will now consider the recommendation, with the new Health Secretary James Murray set to meet with the UKNSC chair. The Department of Health and Social Care stated that Murray "will give full and careful consideration to the recommendation" and would update on the government's response shortly.The committee acknowledged that more research is needed to address evidence gaps, particularly regarding black men. The UKNSC will work with the Transform trial, launched by Prostate Cancer UK, to gather more data. It was noted as "particularly important" that a "sufficient number" of black men be invited to participate in this trial.

Legal Threats Emerge Over UK‑US Drug Pricing AgreementCampaigners Global Justice Now and Just Treatment have issued a nine‑page “letter before claim” stating they will pursue a judicial review if the Department of Health and Social Care (DHSC) does not repeal a statutory instrument that lets the health secretary overrule the independent judgment of NICE on NHS drug prices.Statutory Instrument Gives Ministers Power to Override NICEThe secondary legislation came into force last month, granting ministers authority to direct how much the NHS should pay for certain medicines.Both groups argue this constitutes an “unlawful power grab” that breaches the Health and Social Care Act 2012.Former health secretary Andrew Lansley has also labelled the instrument unlawful.Opaque Cost Data Undermines Parliamentary ScrutinyMPs from multiple parties have criticised the government’s refusal to publish an impact assessment of the decade‑long UK‑US deal.No concrete figures on the long‑term cost to the NHS have been released, limiting debate in the Commons.Potential Erosion of NICE Independence Risks NHS Price ControlsNICE is globally respected for its independent cost‑effectiveness assessments.Overriding its recommendations could lead to higher drug prices for the NHS, undermining the mechanism that keeps “big pharma’s overinflated prices” in check.Campaigners warn the move jeopardises patient safety and democratic oversight.Future Legal Battles May Shape UK Drug Policy LandscapeIf the judicial review proceeds, courts will examine whether the statutory instrument conflicts with existing health legislation.Continued parliamentary pressure may force the government to renegotiate aspects of the UK‑US tariff‑free drug export agreement.The outcome could set a precedent for how future health‑related secondary legislation is crafted and scrutinised.

Palantir’s senior UK representative has warned ministers against yielding to ideologically motivated campaigners as they explore the possibility of terminating a £330 million NHS contract for the company’s Federated Data Platform (FDP).The FDP, an AI‑enabled system intended to unify patient information across the health service, is part of a broader portfolio that includes contracts with the Ministry of Defence, several police forces and the UK’s financial regulator.Louis Mosley, executive vice‑chair of Palantir UK, told The Times that abandoning the deal would jeopardise patient care and hinder progress on the NHS’s most pressing challenges. He highlighted that the platform is projected to generate £150 million in benefits by the end of the decade, delivering a £5 return for every pound spent.According to the Financial Times, senior officials have begun informal discussions about activating a break clause that would allow the FDP’s operation to be transferred to an alternative provider once the system becomes fully operational next year.Palantir, a US‑based data‑analytics firm with ties to the Israeli and US militaries and former U.S. Immigration and Customs Enforcement contracts, has faced sustained opposition from the British Medical Association, which has long criticised the use of its technology in patient‑care settings.Health officials acknowledge the reputational risk, noting that the controversy now extends beyond traditional Labour‑left and Green Party critics. A Department of Health and Social Care spokesperson emphasised that the FDP is designed to improve care coordination, accelerate cancer diagnoses and increase treatment capacity, while maintaining strict data‑security safeguards.Health Secretary Wes Streeting, speaking on the Guardian Politics Weekly podcast, recognised public unease about Palantir’s political affiliations, referencing founder Peter Thiel’s right‑wing connections. He reassured listeners that Palantir does not have direct access to patient data, stating, "The platform is operated by us; Palantir never sees the data."Adoption of Palantir’s technology within the NHS has risen from 118 to 151 organisations since June, though it remains short of the government’s target of 240 organisations by year‑end. Labour backbencher Clive Lewis noted that the issue is becoming a visible concern for voters, reflecting broader anxieties about AI and foreign‑owned infrastructure in critical public services.